About > Company

The Adial Vision

To build the world’s leading addiction-focused pharmaceutical company

Adial is focused on developing therapies for the treatment and prevention of addiction and related disorders. Our lead investigational drug candidate, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in patients with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Through its subsidiary, Purnovate, is also developing adenosine analogs for the treatment of pain, asthma, cancer, diabetes, and other disorders.


Adial is at an important inflection point with our accomplishment of significant milestones. Addiction is a devastating disease that takes an enormous toll on our families, communities, country and the economy. I am excited to lead Adial as we advance our mission to bring life-transforming therapies to patients who are in need. This begins with our lead investigational drug candidate, AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder and other addictions. Importantly, we have positive clinical data for this treatment in what is a commercially viable patient population. I believe that Adial is well-positioned to advance medicines that address unmet needs in in addiction and other areas, including pain, asthma, cancer, diabetes and inflammation.

Cary J. Claiborne Chief Executive Officer

Having overseen more than 20 AUD and other addiction-related clinical trials during the course of my career, I am invigorated by the rapid progress of our ONWARD Phase 3 trial. Importantly, we remain on target to complete all patient dosing in the first quarter of 2022. I would like to thank our team, our CRO, and the clinical investigators for their hard work in efficiently advancing this important trial. I truly believe that AD04 holds enormous promise for the millions of Americans and individuals around the world suffering from addiction.

Bankole A. Johnson, D.SC., M.D. Founder and CMO

The Adial Story

Watch our Story

Adial History

Adial was founded on the ground-breaking work of Bankole A. Johnson, M.D., D.Sc. Dr. Johnson began his work in the 1990’s and, once the genome was unlocked, focused on understanding the genetics behind addiction. After animal studies, imaging studies, and early clinical work, he hypothesized that a serotonin-3 blocker might help people with certain genetics related to the serotonin system. After a Phase 2 study conducted by the University of Virginia at three sites in Virginia and one site in Texas, he met William Stilley and Adial Pharmaceuticals was founded in 2010 and began operations in 2011.


Adial Timeline

  • 2010–2011

    Adial Founded

    Licenses AD04 from the University of Virginia

  • 2014

    USPTO grants 1st U.S. patent for AD04 for the treatment of Alcohol Use Disorder (AUD) in genetically targeted patients

  • 2018

    Adial Pharmaceuticals listed on U.S. NASDAQ
    (Ticker: ADIL)

    Adial Pharmaceuticals listed on U.S. NASDAQ
  • 2020

    ONWARD Phase 3

    ADO4 Onward Phase 3 Trials begin

  • 2021

    Adial acquires Purnovate, Inc. and its adenosine platform with potential to generate novel therapies, including a non-opioid pain program.

    Purnovate image

    “The acquisition of Purnovate is transformative for Adial. Adial’s review of specific and proprietary adenosine analog compounds developed by Purnovate as non-opioid alternatives for the treatment of pain, appear promising and the addition of Purnovate’s fully operational laboratory and chemicals library, as well as its intellectual property, substantially increase the value of assets owned and controlled by Adial.”

    William B. Stilley, MBA, Founder and Purnovate CEO
  • 2022

    ONWARD Phase 3 Trials completed

    ONWARD Phase 3 Trial results announced